Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 10/20 | 0.40 |
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | HTR2B | P41595 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12394492 | 1.00 | MTNR1A (0.62) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL340075 | 1.00 | MTNR1A (0.62) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL340076 | 1.00 | MTNR1A (0.62) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Hydrochloric Acid SCHEMBL339856 | 0.99 | MTNR1A (0.60) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Hydrochloric Acid SCHEMBL339855 | 0.99 | MTNR1A (0.60) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Hydrochloric Acid SCHEMBL29794521 | 0.99 | MTNR1A (0.60) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Bromide SCHEMBL2879815 | 0.99 | MTNR1A (0.60) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL28361707 | 0.85 | MTNR1A (0.65) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL28357968 | 0.85 | MTNR1A (0.65) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL12056685 | 0.85 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775240-A | Rametidine in Process for the preparation of intermediates | 广东赛烽医药科技有限公司 | 2025-04-08 | — | — | CN | claimed |
| EP-1792899-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-07-09 | — | — | EP | claimed |
| CN-119775240-A | Rametidine in Process for the preparation of intermediates | 广东赛烽医药科技有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119775240-A | Rametidine in Process for the preparation of intermediates | 广东赛烽医药科技有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-117946050-A | Preparation method of ramelteon impurity dimer | 湖南慧泽生物医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117946050-A | Preparation method of ramelteon impurity dimer | 湖南慧泽生物医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2021210920-A1 | METHOD FOR PRODUCING RAMELTEON, AND INTERMEDIATE COMPOUND USED FOR SAME | 제이투에이치바이오텍 주식회사 | 2021-10-21 | — | — | WO | disclosed |
| WO-2021210920-A1 | METHOD FOR PRODUCING RAMELTEON, AND INTERMEDIATE COMPOUND USED FOR SAME | 제이투에이치바이오텍 주식회사 | 2021-10-21 | — | — | WO | disclosed |
| CN-111170970-A | Preparation method of ramelteon | 北京万全德众医药生物技术有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-104119307-A | Preparation method for (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-B]furan-8-yl)ethylamine | CISEN PHARMACEUTICAL CO LTD | 2014-10-29 | — | — | CN | disclosed |
| CN-104119307-A | Preparation method for (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-B]furan-8-yl)ethylamine | CISEN PHARMACEUTICAL CO LTD | 2014-10-29 | — | — | CN | disclosed |
| WO-2009093133-A1 | METHOD FOR DETERMINING THE ENANTIOMERIC PURITY OF INDANE DERIVATIVES | MEDICHEM, S.A. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | disclosed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | disclosed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | disclosed |
| WO-2008151170-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-11 | — | — | WO | disclosed |
| US-20080242877-A1 | Methoxy-indenyl-propionic ester or amide; to produce (S) N-[2-(1, 6, 7, 8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide i.e. Ramelteon; insomnia | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-02 | — | — | US | disclosed |
| US-20080242877-A1 | Methoxy-indenyl-propionic ester or amide; to produce (S) N-[2-(1, 6, 7, 8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide i.e. Ramelteon; insomnia | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-02 | — | — | US | disclosed |
| WO-2008106179-A1 | INTERMEDIATES AND PROCESSES FOR THE SYNTHESIS OF RAMELTEON | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008062468-A2 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE INDENO [5,4-B] FURAN DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242877-A1 | Methoxy-indenyl-propionic ester or amide; to produce (S) N-[2-(1, 6, 7, 8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide i.e. Ramelteon; insomnia | CNR2, PNMT, GABRP | MTNR1A 18/4885MTNR1B 11/4885ABCB11 3708/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | MTNR1A 1689/4885MTNR1B 1969/4885ABCB11 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.